Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Condition:   Multiple Sclerosis
Interventions:   Drug: Pioglitazone;   Drug: clemastine fumarate;   Drug: Dantrolene;   Drug: Pirfenidone
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting